REVUFORJ (REVUMENIB 110MG /160 MG)
Price
FAQ's
Details
Patients Stories
Important Guide
Revumenib is an oral menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with KMT2A rearrangement. It works by disrupting the menin-KMT2A protein interaction that drives leukemia growth, helping leukemia cells mature into normal blood cells and slowing disease progression.

